TransMedics Group, Inc. $TMDX Shares Sold by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. significantly reduced its stake in TransMedics Group by 97.6%, selling 289,072 shares, and now holds just 6,963 shares worth approximately $468,000.
• Several other institutional investors increased their stakes in TransMedics during the same period, with HighTower Advisors LLC raising its holdings by 137.7% and Public Sector Pension Investment Board increasing its position by 27.4%.
• TransMedics Group reported strong quarterly earnings, with $0.92 earnings per share, exceeding analysts' expectations, and generated revenue of $157.37 million, a 37.7% increase year-over-year.

Russell Investments Group Ltd. trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 97.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,963 shares of the company's stock after selling 289,072 shares during the period. Russell Investments Group Ltd.'s holdings in TransMedics Group were worth $468,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. HighTower Advisors LLC increased its holdings in shares of TransMedics Group by 137.7% during the first quarter. HighTower Advisors LLC now owns 18,257 shares of the company's stock valued at $1,228,000 after purchasing an additional 10,575 shares during the period. Trillium Asset Management LLC increased its holdings in shares of TransMedics Group by 7.4% during the first quarter. Trillium Asset Management LLC now owns 35,389 shares of the company's stock valued at $2,381,000 after purchasing an additional 2,442 shares during the period. Public Sector Pension Investment Board increased its holdings in shares of TransMedics Group by 27.4% during the first quarter. Public Sector Pension Investment Board now owns 106,480 shares of the company's stock valued at $7,164,000 after purchasing an additional 22,894 shares during the period. Nuveen LLC acquired a new position in shares of TransMedics Group during the first quarter valued at $5,927,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of TransMedics Group by 104.7% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,309 shares of the company's stock valued at $3,183,000 after purchasing an additional 24,200 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently issued reports on TMDX. Canaccord Genuity Group lifted their target price on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, July 15th. Morgan Stanley lifted their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Oppenheimer lifted their target price on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $145.00 target price (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $123.00.

Insiders Place Their Bets

In related news, insider Anil P. Ranganath sold 686 shares of TransMedics Group stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Trading Down 1.5%

Shares of TMDX opened at $114.96 on Monday. The business's 50-day moving average price is $120.24 and its 200 day moving average price is $103.29. The stock has a market capitalization of $3.92 billion, a P/E ratio of 59.57 and a beta of 2.18. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $172.78. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group's revenue was up 37.7% on a year-over-year basis. During the same quarter last year, the business posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. Analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.